EmailGeneral Commentary: Amarin (AMRN) announced that the U.S. Patent and Trademark Office published a notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/769,885 titled "Highly Stable EPA in a Capsule."
The patent would cover a stable pharmaceutical composition of AMR101 comprising at least 95% EPA and would have a patent term that would expire no earlier than 2030. Joseph Zakrzweski, Chairman and Chief Executive Officer of Amarin said, "This patent application is part of our expanding patent portfolio for Amarin covering AMR101. Amarin is currently prosecuting greater than 25 pending U.S. patent applications with the goal of protecting the commercial potential of AMR101 to 2030 and beyond." AMR101 is Amarin's lead product for the treatment of patients with high triglyceride levels. Triglycerides are fats in the blood and high levels are linked to higher risk of heart disease and stroke.
Gainers on news: K-V Pharmaceutical (KV.A +27.78%) FDA issued further guidance on co's pre-term birth drug Makena; FDA says Makena should be used before compounded drug alternatives Lincare Holdings (LNCR +21.47%) To be acquired by The Linde Group for $41.50 per share in cash ($4.6 bln), a 22% premium to last session's closing price Ampio Pharmaceuticals (AMPE +6.10%) Announced it is continuing with development plan for a combination product to treat both premature ejaculation and erectile dysfunctionDecliners on news: NuPathe (PATH -6.70%) Updated migraine patch NDA resubmission timing: expects to resubmit in July and continues to anticipate a six-month review by the FDA Arena Pharmaceuticals (ARNA -6.66%) Weakness due to uncertainty of commercial launch of co's recently approved weight loss drug Belviq Corcept Therapeutics (CORT -4.90%) Announced underwritten public offering of 11 mln shares of common stock.
Giners on earnings: No notable gainers on earnings Decliners on earnings: No notable decliners on earnings Upgrades/Downgrades: Cytokinetics (CYTK +0.20%) Initiated with a Buy at Needham, target $2.50 Laboratory Holdings (LH -0.37%) Upgraded to Neutral from Sell at Goldman Sangamo BioSciences (SGMO -2.72%) Downgraded to Underweight from Neutral at Piper Jaffray
